Navigation Links
Soligenix Reports Second Quarter 2013 Financial Results, and Highlights Recent Accomplishments
Date:8/12/2013

PRINCETON, N.J., Aug. 12, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today its financial results for the quarter and six months ended June 30, 2013.

Soligenix's revenues for the quarter and six months ended were $0.6 million as compared to $0.8 million for the quarter and $1.5 million as compared to $1.4 million for the six months ended June 30, 2013 and 2012, respectively.  For the six months ended June 30, 2013 compared to June 30, 2012, revenues increased by $0.1 million related to reimbursable costs from the Company's four active government funded programs, most notably its ThermoVax™ thermostability technology grant focused on a novel method of rendering aluminum salt adjuvanted vaccines stable at elevated temperatures. 

Soligenix's net loss was $3.4 million, or $0.28 per share as compared to $1.0 million, or $0.09 per share for the quarter and $4.5 million, or $0.38 per share as compared to $2.4 million, or $0.22 for the six months ended June 30, 2013 and 2012, respectively.  Included in the net loss for the quarter and six months ended June 30, 2013 are non-cash charges of $2.1 million which include a $1.5 million expense related to the exclusive worldwide collaboration with Intrexon Corporation (Intrexon) and a $0.6 million charge due to the change in fair value of liability related to warrants issued in the Company's June 25, 2013 registered public offering.

Research and development expenses were $2.1 million as compared to $0.5 million and $2.9 million as compared to $1.7 million for the quarter and six months ended June 30, 2013 and 2012, respectively.  Included in the current quarter and six months expenses is a $1.5 million non-cash charge related to
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Pricing of Public Offering of Common Stock and Warrants
2. FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer
3. Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohns Disease
4. Soligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments
5. Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration
6. Soligenix to Present at World Vaccine Congress & Expo
7. Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis
8. Soligenix to Present at 15th Annual BIO CEO & Investor Conference
9. Soligenix Announces Formation of Oral Mucositis Medical Advisory Board
10. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
11. Soligenix Reports Third Quarter 2012 Financial Results and Highlights Recent Accomplishments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Egalet Corporation (Nasdaq: EGLT ) ... on developing, manufacturing and marketing innovative pain treatments, ... offering of 6,666,667 shares of its common stock ... share. The gross proceeds to Egalet from this ... before deducting the underwriting discounts and commissions and ...
(Date:7/28/2015)...  Alere Inc. (NYSE: ALR ), a global ... release its financial results for the second quarter ended ... call beginning at 8:30 a.m. ET on Tuesday, August ... updates. The conference call will be ... website, or accessed directly through the following link: ...
(Date:7/28/2015)... CARLSBAD, Calif. , July 28, 2015 ... that it will host a live webcast on Tuesday, ... its second quarter 2015 financial results and report on ... may listen to the call by dialing 877-443-5662 or ... replay will be available for a limited time at ...
Breaking Medicine Technology:Egalet Announces Pricing of Public Offering of Common Stock 2Egalet Announces Pricing of Public Offering of Common Stock 3Egalet Announces Pricing of Public Offering of Common Stock 4Alere to Report Second Quarter 2015 Financial Results on August 4, 2015 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call 3
... GAITHERSBURG, Md., Aug. 23 Iomai Corporation,(Nasdaq: ... efficacy and,safety results from its double-blind Phase 2 ... has been accepted as a "late breaker",presentation at ... held in Chicago Sept. 17 to 20. ...
... Aug. 22 Novavax, Inc.,(Nasdaq: NVAX ) ... entitled,"Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent,Neutralizing ... in,Seattle by Dr. Weimin Liu, University of Alabama ... results of pre-clinical immunological,studies of improved HIV-1 virus-like ...
Cached Medicine Technology:Iomai Announces Data from Phase 2 Field Study of Travelers' Diarrhea Vaccine Accepted for Presentation at ICAAC 2Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference 2Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference 3Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference 4Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference 5
(Date:7/28/2015)... ... 2015 , ... Darryl Worley’s Annual Tennessee River Run events ... of raising money for the Darryl Worley Foundation. Worley will host Wade Hayes, ... Saturday, Oct. 3. , This year’s concert will have a second stage showcasing ...
(Date:7/28/2015)... ... 28, 2015 , ... Autism is the fastest growing serious ... with the disorder. For these families, identifying and paying for the help they ... That’s where Talk About Curing Autism (TACA), a national non-profit organization dedicated to ...
(Date:7/28/2015)... Jose, CA (PRWEB) , ... July 28, 2015 ... ... services, intelligent gateways, and embedded building blocks for edge devices that enable the ... equipped with 4th generation Intel® Core™ i7/i5 processor to provide exceptional computing power ...
(Date:7/28/2015)... ... July 28, 2015 , ... OrthAlign, Inc., a privately held ... system, a palm-sized, single-use navigation device for Total Hip Arthroplasty (cup placement, leg ... in a revolutionary way for Total Knee Arthroplasty surgeries and is now doing ...
(Date:7/28/2015)... FL (PRWEB) , ... July 28, 2015 , ... On ... state officials refused to schedule the hearing of proposed bills and laws revolving the ... of new infections to date. Some vigilante ministers are continuing to hand out clean ...
Breaking Medicine News(10 mins):Health News:Worley’s 14th Tennessee River Run Will Host Wade Hayes, Lorrie Morgan, Tracy Lawrence and Others 2Health News:Worley’s 14th Tennessee River Run Will Host Wade Hayes, Lorrie Morgan, Tracy Lawrence and Others 3Health News:National TACA Autism Conference Offers Hope and Help to Families Affected by Autism 2Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 2Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 3Health News:OrthAlign, Inc. Announces U.S. Commercial Launch of ORTHALIGN PLUS®, the most complete handheld navigation device for use in Total Hip Arthroplasty Surgery 2Health News:OrthAlign, Inc. Announces U.S. Commercial Launch of ORTHALIGN PLUS®, the most complete handheld navigation device for use in Total Hip Arthroplasty Surgery 3Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 2Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 3
... Calif.) In one of the first studies to examine ... researchers have found that women diagnosed with the disease during ... women who have the disease and are not pregnant. The ... of preterm labor, the outcomes for the babies is the ...
... in the March 2009 issue of the Journal ... to improvements in the efficacy of the current tuberculosis ... new role for type I interferon, in which it ... immune response against the bacterium known to cause tuberculosis. ...
... gastrointestinal condition , , THURSDAY, Feb. 26 (HealthDay News) ... new genetic targets for drugs to treat Crohn,s ... inflammation of the gastrointestinal tract. , The Children,s ... method, combining a statistical tool that identifies genes ...
... A large new study provides evidence that ... from Parkinson,s disease. The study was released today and will ... Meeting in Seattle, April 25 to May 2, 2009.The study ... (number of years from first menstruation to menopause) had a ...
... The following release was issued today by the ... court ruled against three families claiming vaccines caused autism ... F Kennedy, JR and David Kirby reported Tuesday on ... into autism following the MMR vaccine. Last week, Banks, ...
... decision issued by the U.S. District Court for the ... for the insurance industry. The February 13 ruling from ... the court entered two months earlier establishing that Texas ... policies to advance defense costs incurred in connection with ...
Cached Medicine News:Health News:No differences in survival or neonatal outcomes in pregnancy-associated colorectal cancer 2Health News:No differences in survival or neonatal outcomes in pregnancy-associated colorectal cancer 3Health News:New discovery gives tuberculosis vaccine a shot in the arm 2Health News:Scientists Discover New Drug Targets for Crohn's Disease 2Health News:Reproductive Factors May Protect Women from Parkinson's Disease 2Health News:Reproductive Factors May Protect Women from Parkinson's Disease 3Health News:On the Heels of Court Ruling Denying Autism-Vaccine Link, U.S. Federal Court Declares MMR Vaccine Caused Autism in a Young Boy 2Health News:Patton Boggs Wins Landmark Insurance Case for Client 2
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: